Protocols: CRO industry poised for steady growth as new work in China explodes (in a good way); Vectura dinged on PhIII Flutiform flop
Shares of the UK’s Vectura dropped early Tuesday after the company conceded that Flutiform had failed a Phase III study for COPD. The failed study, run by Mundipharm, is scuttling plans for a regulatory filing.”Whilst this result is disappointing, Flutiform continues to grow strongly based on the approved asthma indication, which continues to underpin our expectations for future growth of the product,” Chief Executive Officer James Ward-Lilley said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.